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Purpose: Although successful treatment of squamous cell carcinoma (SCC) of the rectum using chemoradiation
therapy (CRT) has been reported, a standard protocol has yet to be established. The aim is to ascertain the
effectiveness of CRT with S-1 for three patients with SCC of the rectum.
Case presentation: We treated three female patients complaining of rectal bleeding. The patients were diagnosed
as having primary SCC of the rectum by means of routine examinations; one of them was a very rare case because
of the presence of two lesions in the lower rectum. We treated the patients using CRT with S1 at a radiation
dose of 1.8 Gy/fraction given five times weekly (Monday to Friday) to a median dose of 59.4 (45 to 59.4) Gy; S-1
(80 mg/m2/day) was administered orally during radiation therapy. One of three patients had an adverse event
involving massive hemorrhage from the tumor. All patients exhibited an excellent response to CRT with S-1; two
patients had a complete response, and one patient had a partial response and underwent a posterior pelvic
exenteration with advancement flap reconstruction as a salvage treatment. Pathological examination of the
resected specimen and lymph nodes revealed no tumor cells indicating a pathological complete response. In
this series, the response rate was 100%.
Conclusions: We suggest that CRT with S-1 be chosen as the first-line therapy for SCC of the rectum. However,
a large study will be required to establish a safe and effective regimen.
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Primary squamous cell carcinoma (SCC) of the anorectum
is a very rare disease and there have been few reports re-
garding SCC in the rectum. Nowadays, chemoradiation
therapy (CRT) with 5-fluorouracil (5-FU) plus mitomycin-
C (MMC) is the recommended treatment for SCC of the
anus based on the findings from a small number of clinical
trials [1-3]; surgery is considered as being a salvage treat-
ment. An optimal treatment for primary SCC of the
rectum has not been established because of the lack of
randomized studies. The choice of the treatment* Correspondence: kingkong@med.toho-u.ac.jp
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in any medium, provided the original work is pdepends on the tumor characteristics, namely, size, lo-
cation, depth of tumor cell invasion, and distant metas-
tasis. Recently, some studies have reported that CRT
might also be effective in the treatment of primary SCC
of the rectum [4-9]. Oral fluoropyrimidines including
S-1, tegafur-uracil (UFT), and capecitabine have been
developed as a therapeutic alternative to the venous
infusion of 5-FU. S-1 is an oral anticancer drug com-
posed of tegafur (a prodrug of 5-FU), 5-chloro-2, 4-
dihydropyrimidine (CDHP; gimeracil), and potassium
oxonate that has the following benefits. It increases the
blood 5-FU concentration by inhibiting the metabolism
of 5-FU by means of dihydropyrimidine dehydrogenase,
and it also enhances the radiation response of colon can-
cer as compared with 5-FU. In the present case report, weis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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responded to CRT with S-1.
Case presentation
Patient 1
A 54-year-old woman was diagnosed as having primary
SCC of the rectum at another institution. Although abdo-
minoperineal resection (APR) was proposed as a radical
treatment at the institution, the patient consulted our in-
stitution about alternative treatments including CRT. A
colonoscopy revealed the presence of an ulcerative lesion
in the lower rectum. Histological analysis of biopsies taken
at the time of the colonoscopy revealed SCC. There were
no lesions detected at any site other than the rectum using
computed tomography (CT) and magnetic resonance im-
aging (MRI). Lymph node metastasis was found in the
mesorectum. Finally, we diagnosed the lesions as primary
SCC (cT3 N2a M0, cStage III B) of the rectum. We pro-
posed laparoscopic intersphincteric resection (ISR) for the
lesion as a radical treatment, but the patient refused the
operation and requested CRT. Therefore, CRT with S-1
was administered. Radiation therapy (RT) at a dose of
1.8 Gy/fraction was given five times weekly (Monday to
Friday) to a total dose of 59.4 Gy; S-1 (80 mg/m2/day)
was administered orally for a total of 55 days (33 days
during RT and 22 days alone). The planned CRT with
S-1 was achieved without adverse events. The tumor
marker, squamous cell carcinoma antigen (SCC Ag),
had normalized after CRT with S-1 from a level of 9.3
to 0.9 ng/ml. Colonoscopy revealed the complete responseFigure 1 Effectiveness of chemoradiation therapy with S-1 for patient 1
was showing an ulcerative lesion in the lower rectum (A). Lymph node metast
(C). After chemoradiation therapy with S-1, colonoscopy showed a polyp
lymph node metastasis had disappeared (D).of the lesions, and there were no tumor cells detected in
the biopsies taken during colonoscopy (Figure 1). The pa-
tient was regularly followed up every 6 months, but there
were no findings of recurrence and anorectal dysfunction
over a follow-up period of 3 years and 8 months.
Patient 2
An 84-year-old woman visited our institution complain-
ing of bloody stools. Digital rectal examination at the
outpatients department of our institution revealed a tumor
located at about 4 cm from the anal verge. Additionally, a
colonoscopy detected another lesion in the lower rectum.
Histological evaluation of biopsies taken at the time of the
colonoscopy revealed SCC. There were no lesions detected
at any other site using CT and MRI. Finally, we diagnosed
the lesions as primary SCC of the rectum (cT3 N0 M0,
cStage II A). We proposed laparoscopic ISR for these le-
sions as a radical treatment, but the patient refused the
operation because of her advanced age. Consequently,
CRT with S-1 was administered for the treatment of these
lesions. RT at a dose of 1.8 Gy/fraction was delivered five
times weekly (Monday to Friday) to a total dose of 59.4
Gy, and S-1 (80 mg/m2/day) was given orally for a total of
50 days (33 days during radiation therapy and 17 days
alone). The planned CRT with S-1 was achieved safely
without adverse events. The tumor marker, SCC Ag, had
normalized after CRT with S-1 from a level of 6.8 to 0.9
ng/ml. Colonoscopy showed a complete response for both
lesions, and there were no tumor cells in biopsies taken
in the colonoscopy (Figure 2). The patient was regularlyevaluated by colonoscopy and computed tomography. Colonoscopy
asis in the mesorectum was suspected using computed tomography
oid lesion (B). Biopsies revealed that there were no tumor cells, and
Figure 2 Colonoscopy findings of patients 2. Colonoscopy images from patient 2. Two lesions are present in the rectum (A, B). No lymph
node metastasis was detected using imaging. After radiation therapy at a total dose of 59.4 Gy in combination with S-1, the lesions disappeared
(C, D). The patient was regularly followed up at 6-month intervals, but no recurrence was found over a follow-up period of 2 years and 1 month.
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findings of recurrence and anorectal dysfunction over a
follow-up period of 2 years and 1 month.
Patient 3
A 64-year-old woman visited our institution complaining
of analgia. We suspected rectal cancer from the findings
of digital examination and immediately hospitalized the
patient to observe the lesion and perform open biopsy
under spinal anesthesia. It was found that the tumor in
the lower rectum had massively invaded the perineum but
there were no findings including anal involvement and fis-
tulous tract lined by rectal tumor. Histological analysis of
biopsies revealed SCC. Additionally, MRI showed inva-
sion of the levator ani and the vagina (T4b), with lymph
node metastases involvement including the inguinal
lymph nodes. However, there was no distant metastasis.
We diagnosed the lesion as primary SCC of the rectum.
The SCC was staged as cT4b N2b M0, cStage III C using
the TNM classification. CRT with S-1 for the locally ad-
vanced lesion was planned as a primary treatment. RT at a
dose of 1.8 Gy/fraction was delivered five times weekly
(Monday to Friday) to a total dose of 59.4 Gy, and S-1 (80
mg/m2/day) was given orally. However, during treatment,
the patient developed a massive hemorrhage from theprimary lesion and required a blood transfusion. The
adverse event was considered as grade 3 in the common
terminology criteria for adverse events version 4.0. Finally,
RT of a total dose of 45 Gy and S-1 (80 mg/m2/day) for a
total of 30 days were performed. After CRT with S-1, the
level of SCC Ag had decreased from a level of 54.3 to 1.2
ng/ml. Evaluation using MRI indicated that the size of the
primary lesion had decreased (Figure 3). Consequently, we
performed a posterior exenteration with advancement flap
reconstruction as salvage therapy. Pathological findings
revealed no tumor cells in either the resected specimen
or the lymph nodes. Therefore, the patient was judged to
have achieved a pathological complete response. After
leaving the hospital, the patient was followed up regularly
at our outpatient department. She complained of lumbar
pain at 1 year after treatment. MRI of the spine showed
bone metastasis. RT was administered to palliate the lum-
bar pain induced by bone metastasis. Finally, the patient
died of bone and liver metastases at 1 year and 2 months
after surgery.
Discussion
We treated three patients with SCC of the rectum in our
institution between 2000 and 2013 (Table 1). The ther-
apy for SCC of the rectum was approved by the Toho
Figure 3 Magnetic resonance imaging of patient 3. Magnetic resonance image of patient 3 with squamous cell carcinoma of the rectum (A, B).
The tumor was diagnosed as being at clinical stage T4b N2b M0. The patient received chemoradiation therapy with S-1 (C, D), and then, a posterior
pelvic exenteration with advancement flap reconstruction was performed as salvage therapy. Pathological findings revealed no tumor cells in either
the resected specimen or the lymph nodes (i.e., a pathological complete response).
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Review Board (No. 26-231). All of the patients were fe-
male and complained of rectal bleeding. Colonoscopy
revealed a tumor located in the lower rectum, and
histological analysis of biopsies taken at the time of col-
onoscopy indicated SCC. CT and MRI examinations did
not detect lesions at any other site. Finally, the lesions
were diagnosed as primary SCC of the rectum. The occur-
rence of SCC in the colon and rectum is much rarer than
in that the anus. In particular, the occurrence of two le-
sions in the rectum is extremely rare. The mechanism
of the development of SCC in the rectum remains elu-
sive. Human papillomavirus (HPV) has been associated
with many squamous cell carcinomas such as oral, vagi-
nal, esophageal, and anal cancer and so on. It is pos-
sible that SCC of the rectum is associated with HPV
infection as well, but there are no firm evidences for a
cause or relationship between infection with HPV and
SCC of the rectum [10,11]. In addition, several cases
have been reported in patients with ulcerative colitis
[12-15] and in patients with infections including Schis-
tosomiasis [16] and Entamoeba histolytica [17].
Currently, treatment for SCC of the rectum depends
on tumor size, location, depth of invasion, lymph nodeinvolvement, and the presence of distant organ metasta-
sis. Local excision is appropriate for T1 or selected T2
tumor, and low anterior resection or abdominoperineal
resection is required for advanced tumor. Dyson et al.
[18], however, reported that prognosis for patients with
SCC of the rectum who received surgical treatment was
poor. Surgical treatment also accompanies some problems
such as surgical site infection, leakage, and urinary/sexual
complications. Some researchers have reported several
cases treated using CRT as the primary therapy or in
conjunction with surgery [14,15,19-24]. Recently, Clark
et al. [4], Rasheed et al. [5], and Sturgeon et al. [25] re-
ported the success of CRT in the treatment of SCC of
the rectum. Their regimens involved primary 5-FU-based
treatment together with either MMC or cisplatin, which
were the same regimens as used for SCC of the anus. Add-
itionally, some experimental treatments using CRT with
S-1 + cisplatin, S-1 +MMC, and S-1 alone for SCC of the
anus have been reported in Japanese studies [26-34].
These studies found that all patients treated using CRT
with S-1 alone had an excellent response to treatment
(Table 2). S-1 is an oral anticancer drug that has the
following benefits. S-1 increases the blood 5-FU con-
centration by inhibiting the metabolism of 5-FU by means
Table 1 Patients treated with chemoradiation therapy with S-1







1 F 54 Rb 21.5 III B 59.4/33 S-1 alone None 9.3 0.9 - CR Disease-free for 3 years
8 months
2 F 84 Rb 42.6 II A 59.4/33 S-1 alone None 6.8 0.9 - CR Disease-free for 2 years
1 month
3 F 62 Rb-a 44.4 III C 45/25 S-1 alone Hemorrhage (G-3) 54.3 1.2 PPE pCR Bone and liver metastasis
at 1 year 2 months
Rb 125
RT, radiation therapy; CT, chemotherapy; CTCAE, common terminology criteria for adverse events; SCC Ag, squamous cell carcinoma antigen; CRT, chemoradiation therapy; Ra, rectum above the peritoneal reflection;









Table 2 Reported cases of squamous cell carcinoma of the anus treated chemoradiation therapy with S-1
Author Gender Age Location cStage RT (Gy) Chemotherapy Response Prognosis
Miyamoto S et al. [26] 2009 F 61 AC IV 30 S-1 + CDDP CR Disease-free for 20 months
Kuga Y et al. [27] 2009 F 76 AC III 50 S-1 + CDDP CR NR
Shiozawa M et al. [28] 2010 F 48 AC III 60 S-1 + MMC CR Disease-free for 2 years 7 months
F 65 AC III 55.8 S-1 + MMC CR Disease-free for 2 years 4 months
F 71 AC III 58.0 S-1 + MMC CR Disease-free for 8 months
Hata T et al. [29] 2011 F 53 AC I 45 S-1 alone CR NR
Baba H et al. [30] 2011 F 79 AC III 66 S-1 alone CR Disease-free for 10 months
Nitori N et al. [31] 2011 F 58 AC IV 30 S-1 + CDDP NR Dead at 16 months
Kuroda M et al. [32] 2012 F 81 AC IV 50.4 S-1 + CDDP CR Disease-free for 1 year 3 months
Sato H et al. [33] 2012 F 83 AC II 60 S-1 alone CR Local recurrence at 9 months and dead at
15 months after CRT
Murata K et al. [34] 2012 F 76 AC II 60 S-1 alone CR Recurrence at 2 years
RT, radiation therapy; AC, anal canal; CR, complete response; NR, not reported.
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significant effectiveness to adenocarcinoma with high-
DPD activity of the stomach [35-37], pancreas [38,39],
biliary tract [40-42], and so on [43,44]. Moreover, S-1 is
more effective as a tumor radiation response enhancer
than 5-FU [45,46]. In reports by Vezeridis et al. [47]
and Maritinez-Gonzalez et al. [20], disease control for
SCC of the rectum treated using 5-FU and RT was not
sufficient. In our series, RT was delivered at a total dose
of 59.4 Gy in 1.8 Gy/fraction 5 days weekly (Monday to
Friday) over a period of 33 days, and S-1 (80 mg/m2/
day) was given orally during RT. Patients 1 and 2 were
able to safely undergo treatment with S-1, whereas pa-
tient 3 was not. Regarding the effectiveness of treat-
ment, all patients had an excellent tumor response;
there was a complete response in two patients and a
partial response in one. Although patient 3 required a
posterior pelvic exenteration with advancement flap re-
construction as a salvage therapy, pathological findings
revealed no tumor cells in either the resected specimen
or the lymph nodes. Therefore, the response rate was
100% in this series. Phan et al. [48] and Lukan et al. [49]
have reported on the treatment of refractory SCC of the
anus using cetuximab. Molecular-targeted therapy such as
cetuximab for SCC with an epithelial growth factor recep-
tor might be useful in the treatment of a refractory SCC,
such as that seen in patient 3.Conclusions
The results suggested that CRT with S-1 was chosen as
the first-line therapy for SCC of the rectum; although,
surgery might be an effective salvage therapy. Evaluation
of this modality in a large series of patients with SCC
of the rectum will be required to establish safety and
efficacy.Consent
Informed consent was obtained from the patients for
publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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